Eli Lilly starts late-stage study of coronavirus drug in nursing homes

Eli Lilly starts late-stage study of coronavirus drug in nursing homes

Director of the National Institute of Allergy and Infectious Diseases Anthony Fauci said he expects results from the mid-stage study by October or early November. These units include a custom retrofitted recreational vehicle to support mobile labs and clinical trial material preparation, along with a trailer truck that will deliver all clinical trial supplies needed to create an on-site infusion clinic. The Phase 3 trial will initially enroll some 300 volunteers around the world who have been hospitalized with mild to moderate COVID-19 with fewer than 13 days of symptoms. To further minimize the burden on these facilities that normally do not conduct clinical trials, additional staff will be at the facilities to assist with the operations of the study. Even after this, we are taking this challenge so that the needy people can be helped.

More than half of COVID-19 deaths in IN have occurred in nursing homes, according to data collected by the state.

The medicine is an antibody against the new coronavirus called LY-CoV555, which was identified in the blood sample of a recovered patient by Canada's Abcellera Biologics. Researchers essentially cloned antibodies from one of the first US patients to recover from COVID-19, hoping those proteins help the immune system fight the virus or prevent it from taking hold. Lilly will deploy its mobile research unit fleet in response to outbreaks of the virus at long-term care facilities across the U.S. It was then developed synthetically for mass production by US-based Lilly Research Laboratories in partnership with Abcellera. Patients will also receive pulse oximetry tests to determine the therapeutic effect on blood oxygen levels.

The drug will test whether a drug called LY-CoV555, created to neutralize the coronavirus's infectious "spike" protein can keep exposed people from developing the infection. Studies already under way are testing whether the drug is safe for hospitalized Covid-19 patients, and whether it can clear viral loads and keep patients with milder disease out of the hospital. Efficacy data are not yet available. The company said its drug may get government approval by the end of 2020.

Stephen Hahn discusses combatting the coronavirus through public health guidelines and the development of therapeutics.

Related Articles